1-6 of 6
John J. Crowley
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Overview: Progression-Free Survival as an Endpoint in Clinical Trials with Solid Tumors

Ronald L. Korn, John J. Crowley
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (10): 2607–2612.
https://doi.org/10.1158/1078-0432.CCR-12-2934
Published: 12 May 2013
View article titled, Overview: Progression-Free Survival as an Endpoint in Clinical Trials with Solid Tumors
Open the PDF for Overview: Progression-Free Survival as an Endpoint in Clinical Trials with Solid Tumors in another window
Journal Articles

Design of a Phase III Clinical Trial with Prospective Biomarker Validation: SWOG S0819

Mary W. Redman, John J. Crowley, Roy S. Herbst, Fred R. Hirsch, David R. Gandara
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (15): 4004–4012.
https://doi.org/10.1158/1078-0432.CCR-12-0167
Published: 30 July 2012
View article titled, Design of a Phase III Clinical Trial with Prospective Biomarker Validation: SWOG S0819
Open the PDF for Design of a Phase III Clinical Trial with Prospective Biomarker Validation: SWOG S0819 in another window
Includes: Supplementary data
Journal Articles

Cure Models as a Useful Statistical Tool for Analyzing Survival

Megan Othus, Bart Barlogie, Michael L. LeBlanc, John J. Crowley
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (14): 3731–3736.
https://doi.org/10.1158/1078-0432.CCR-11-2859
Published: 15 July 2012
View article titled, Cure Models as a Useful Statistical Tool for Analyzing Survival
Open the PDF for Cure Models as a Useful Statistical Tool for Analyzing Survival in another window
Includes: Supplementary data
Journal Articles

Randomized Phase III Clinical Trial Designs for Targeted Agents

Antje Hoering, Mike LeBlanc, John J. Crowley
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (14): 4358–4367.
https://doi.org/10.1158/1078-0432.CCR-08-0288
Published: 15 July 2008
View article titled, Randomized Phase III Clinical Trial Designs for Targeted Agents
Open the PDF for Randomized Phase III Clinical Trial Designs for Targeted Agents in another window
Journal Articles

Phase I Study of Tirapazamine Plus Cisplatin/Etoposide and Concurrent Thoracic Radiotherapy in Limited-Stage Small Cell Lung Cancer (S0004): A Southwest Oncology Group Study

Quynh-Thu Le, Jason McCoy, Stephen Williamson, Janice Ryu, Laurie E. Gaspar, Martin J. Edelman, Shaker R. Dakhil, Stanley D. Sides, John J. Crowley, David R. Gandara
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (16): 5418–5424.
https://doi.org/10.1158/1078-0432.CCR-04-0436
Published: 24 August 2004
View article titled, Phase I Study of Tirapazamine Plus Cisplatin/Etoposide and Concurrent Thoracic Radiotherapy in Limited-Stage Small Cell Lung Cancer (S0004): <subtitle>A Southwest Oncology Group Study</subtitle>
Open the PDF for Phase I Study of Tirapazamine Plus Cisplatin/Etoposide and Concurrent Thoracic Radiotherapy in Limited-Stage Small Cell Lung Cancer (S0004): <subtitle>A Southwest Oncology Group Study</subtitle> in another window
Journal Articles

Cisplatin, Etoposide, and Paclitaxel with Granulocyte Colony-Stimulating Factor in Untreated Patients with Extensive-Stage Small Cell Lung Cancer: A Phase II Trial of the Southwest Oncology Group

Karen Kelly, Laura Lovato, Paul A. Bunn, Jr., Robert B. Livingston, Jeffrey Zangmeister, Sarah A. Taylor, Debasish Roychowdhury, John J. Crowley, David R. Gandara
Journal: Clinical Cancer Research
Clin Cancer Res (2001) 7 (8): 2325–2329.
Published: 01 August 2001
View article titled, Cisplatin, Etoposide, and Paclitaxel with Granulocyte Colony-Stimulating Factor in Untreated Patients with Extensive-Stage Small Cell Lung Cancer: <subtitle>A Phase II Trial of the Southwest Oncology Group</subtitle>
Open the PDF for Cisplatin, Etoposide, and Paclitaxel with Granulocyte Colony-Stimulating Factor in Untreated Patients with Extensive-Stage Small Cell Lung Cancer: <subtitle>A Phase II Trial of the Southwest Oncology Group</subtitle> in another window